Loading…

Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation

CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is characterized by poor prognosis after frontline immunochemotherapy. This retrospective study investigated the effect of consolidative radiation after systemic treatment in newly diagnosed stage I-II de novo CD5+ DLBCL. In this study, 22 pati...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2022-05, Vol.63 (6), p.1369-1374
Main Authors: Ge, Jurui, Xia, Yaqin, Sun, Zhenchang, Zhang, Lei, Li, Xin, Li, Ling, Wang, Xinhua, Zhang, Xudong, Li, Zhaoming, Nan, Feifei, Wan, Wenjuan, Xu, Duo, Ding, Jiayin, Fu, XiaoRui, Zhang, Mingzhi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is characterized by poor prognosis after frontline immunochemotherapy. This retrospective study investigated the effect of consolidative radiation after systemic treatment in newly diagnosed stage I-II de novo CD5+ DLBCL. In this study, 22 patients received consolidative radiotherapy (RT) after immunochemotherapy (chemotherapy + RT group) and 28 patients received chemotherapy alone. Patients who received chemotherapy alone had a significantly shorter PFS and OS than those who received consolidative radiotherapy. The five-year PFS rates for the chemotherapy + RT and chemotherapy alone groups were 75.1% and 40.5%, respectively. The five-year OS rates for the chemotherapy + RT and chemotherapy alone groups were 84.2% and 50.1%, respectively. Even after receiving consolidation radiotherapy, 2/22 (9.1%) patients experienced CNS relapse. Age >60 years and lack of radiotherapy were independent prognostic factors for PFS and OS. Ki-67 (≥80%) was an independent prognostic factor for poor OS. Consolidative radiotherapy might be a good option for stage I-II CD5+ DLBCL, but further investigation is needed.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428194.2021.2023742